Recruitment commenced for EMD-RX5 Phase 1 Study
Released
Released
Announcement PDF
ASX Announcement
09 Mar 2022
Recruitment commenced for EMD-RX5 Phase 1 Study
Highlights:
●
Participant recruitment, screening and consenting has commenced for Emyria’s
Phase 1 clinical trial of EMD-RX5; dosing expected by the end of March 2022
●
The Phase 1, 2-way cross-over clinical trial of EMD-RX5 will assess the safety and
bioavailability of EMD-RX5 compared to Epidyolex in 12 healthy human volunteers
who will receive both cannabinoid treatments; Epidyolex is the only CBD-only
medicine formally registered with the TGA and the FDA
●
EMD-RX5 is a proprietary, highly bioavailable oral formulation of ultra-pure CBD,
anticipated to support multiple TGA and FDA registration programs
●
EMD-RX5 is initially targeting TGA registration as an over-the-counter (Schedule 3),
CBD treatment for the symptoms of psychological distress
●
The pivotal Phase 3 study required for registration is expected follow immediately
after conclusion of the Phase 1 trial pending successful ethics approval; since
Emyria’s extensive and proprietary Real World Data has informed the selection of the
target indication, a Phase 2 study is not anticipated to be required
Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotechnology
company leveraging real-world patient data to develop treatments for unmet needs, is
pleased to announce participant recruitment, screening and consenting has commenced for
the EMD-RX5 clinical development program.
EMD-RX5 is an ultra-pure, highly bioavailable cannabidiol (CBD) capsule with potential to
become a registered treatment for multiple indications. EMD-RX5 is the Company’s first,
proprietary cannabinoid-based medical treatment.
Emyria is initially seeking registration of EMD-RX5 with the TGA as a low-dose, Schedule 3,
“over-the-counter” CBD treatment for the symptoms of psychological distress.
Psychological distress is a common mental health problem affecting ~15% of Australian
adults [1] with a rising prevalence.Psychological distress is a state of emotional suffering
typically characterised by symptoms of depression and anxiety which often coexists with a
wide range of chronic conditions [2]. There is currently no over-the-counter treatment for the
relief of short-term symptoms of psychological distress.
1
The full, end-to-end EMD-RX5 development program - encompassing proprietary
formulation design, at-scale GMP manufacturing and all clinical trials - has been designed
to meet the registration requirements of both the TGA and FDA.
Recent pharmacokinetic (PK) studies comparing EMD-RX5 to Epidyolex oil
demonstrated that EMD-RX5 had a higher bioavailability profile compared to Epidyolex.
(See ASX announcement 15 DEC 2021). Epidyolex is sold by Jazz Pharmaceuticals
(NASDAQ: JAZZ) and is the only registered CBD medicine with both the TGA and FDA.
The pivotal Phase 3 clinical trial protocol required for registration has already been
developed and, pending successful ethics approval, is expected to commence
immediately following the Phase 1 trial.
Analysis of Emyria’s extensive and proprietary Real World Data has informed the
selection of the target indication for EMD-RX5 and therefore a Phase 2 study is not
anticipated to be required for registration. Ongoing analysis of Emyria’s Real World Data is
also informing adjacent indications for EMD-RX5 and additional dose form opportunities
for Emyria’s expanding drug product pipeline.
Emyria’s Managing Director, Dr. Michael Winlo said: “ Emyria’s first registration
program is aimed at developing an over-the-counter, Schedule 3 treatment targeting the
symptoms of psychological distress - a growing global mental health concern affecting
about 15% of all adults in Australia alone and which currently has no over-the-counter
treatment available.
EMD-RX5 also meets the strict requirements for product purity with both the TGA in
Australia and the FDA in the USA, and as such, we believe EMD-RX5 has the potential to
become a registered treatment in additional markets and for multiple clinical
indications.
Since the EMD-RX5 clinical development program was developed with insights from
Emyria’s growing Real-World Data asset, the Company is able to move quickly from
Phase 1 through to a Pivotal Phase 3 clinical trial.
Uniquely amongst cannabidiol registration programs, Emyria’s Phase 1 clinical trial will
directly compare the bioavailability of EMD-RX5’s proprietary formulation to the only
successfully registered and reimbursed CBD oil in the global market to date, Epidyolex.
I look forward to providing further updates on EMD-RX5 and our expanding cannabinoid
portfolio.”
This announcement has been approved and authorised for release by the Managing
Director of Emyria Limited.
For further information:
Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com
Lexi O’Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
investors@emyria.com
Andrew Williams
Media Relations
+61 (0) 412 614 125
awilliams@emyria.com
2
REFERENCES:
[1] Australian Institute of Health and Welfare 2018. Australia’s health 2018. Australia’s health
series no. 16. AUS 221. Canberra: AIHW.
[2] Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR, Nemeroff CB,
Bremner JD, Carney RM, Coyne JC, Delong MR, Frasure-Smith N, Glassman AH, Gold PW,
Grant I, Gwyther L, Ironson G, Johnson RL, Kanner AM, Katon WJ, Kaufmann PG, Keefe FJ,
Ketter T, Laughren TP, Leserman J, Lyketsos CG, McDonald WM, McEwen BS, Miller AH,
Musselman D, O'Connor C, Petitto JM, Pollock BG, Robinson RG, Roose SP, Rowland J,
Sheline Y, Sheps DS, Simon G, Spiegel D, Stunkard A, Sunderland T, Tibbits P Jr, Valvo WJ.
Mood disorders in the medically ill: scientific review and recommendations. Biol
Psychiatry. 2005 Aug 1;58(3):175-89. doi: 10.1016/j.biopsych.2005.05.001. PMID: 16084838.
About Emyria (www.emyria.com)
Emyria Limited is a clinical stage biotech developing multiple treatments for unmet needs
powered by real-world patient data. Emyria’s model is aimed at accelerating treatment
development and improving patient care.
Emyria’s Treatments target unmet needs and are focused on obtaining approval from
major global regulators. Emyria’s drug development programs are informed by insights
generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical
evidence that is gathered with patients across Emyria’s independent clinical services
(Emerald Clinics - www.emeraldclinics.com.au)
Emyria Data provides deep treatment insights and is therefore a source of unique IP,
strategically designed drug development and personalised care programs.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the
Company, the company’s strategy, future operations, and other statements containing the words
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements. Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors, including: the Company’s
ability to successfully develop its product candidates and timely complete its planned clinical
programs and the Company’s ability to obtain marketing approvals for its product candidates. In
addition, the forward-looking statements included in this press release represents the Company’s
views as of the date hereof. The Company anticipates that subsequent events and developments
will cause the Company’s views to change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company specifically disclaims any
obligation to do so. These forward-looking statements should not be relied upon as representing
the Company’s views as of any date subsequent to the date hereof.
3
Share your feedback
Discover